RK-582 / Riken - LARVOL DELTA

RK-582, a tankyrase inhibitor, attacks Wnt-driven colorectal cancer cells with short-type APC mutations and high β-catenin expression (AACR 2026) - "In summary, RK-582 targets the Wnt/β-catenin pathway, a key cancer pathway previously considered undruggable. An investigator-initiated first-in-human clinical trial of this drug is currently ongoing, and these findings are expected to contribute to the development of an innovative therapy for unresectable advanced and recurrent CRC."

First-in-human • IO biomarker • Colorectal Cancer • Oncology • Solid Tumor • APC • AXIN1 • BRAF • CTNNB1 • KRAS • PIK3CA